Symptoms aspect
Elinzanetant Shows Promise in Reducing Hot Flashes in Women Undergoing Breast Cancer Therapy
Elinzanetant, Vasomotor Symptoms, Breast Cancer, Adjuvant Endocrine Therapy, Hot Flashes, Non-Hormonal Treatment
Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment
Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning
Elinzanetant Demonstrates Sustained Efficacy Over One Year in Managing Menopausal Vasomotor Symptoms
Elinzanetant, Menopause, Vasomotor Symptoms, Sleep Disturbances, Non-Hormonal Treatment, Bayer
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial
Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment
Palisade Biotechnology’s Novel Ulcerative Colitis Treatment Shows Promising Results in Preclinical Studies
Palisade Biotechnology, ulcerative colitis, preclinical studies, nontoxic, mice, dogs, drug development, inflammatory bowel disease, treatment, prevention, symptoms
Bayer’s New Drug Shows Promising Phase III Results for Menopause Symptom Relief
Bayer, Phase III results, menopause symptoms, drug, clinical trial, hot flashes, night sweats, hormone therapy
Minerva’s Roluperidone for Schizophrenia Symptoms Denied Approval by FDA
United States Food and Drug Administration, MFSD1 gene, Symptoms aspect, Schizophrenia, New Drug Application